J&J
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Citigroup and J&J Snack have been highlighted as Zacks Bull and Bear of the Day
Citigroup's strong Q2 results, rising earnings estimates and low valuation fuel its Bull of the Day status, while JJSF faces weaker outlook.
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?
J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others
Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.
Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory
Johnson & Johnson’s second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed. J&J on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. “I think the second quarter was just an affirmation of the first quarter,” Chief Financial Officer Joe Wolk said in an interview with Barron’s. “Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company’s history.”
Inflation, Bank of America, Wells Fargo, Goldman, ASML, J&J, and More to Watch This Week
Big banks kick off earnings season this week, which will also bring reports from GE Aerospace, Netflix, and Taiwan Semi. In economic news, we’ll get the consumer and producer price indexes, and retail sales data.
J&J wins FDA approval for dual-energy ablation catheter
Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.
J&J's Innovative Medicine Business in Q2: Here's What to Watch
JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.
Salesforce looks to strengthen its AI platform — plus, a positive note for J&J
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded with heavyweights from Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk, J&J, and Broad Institute establishing that the industry's digital future now rests on the 'first mile' of lab data integrity.
Key People
No individuals linked to this entity yet.
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro